{
    "clinical_study": {
        "@rank": "1643", 
        "arm_group": [
            {
                "arm_group_label": "NeutraSal", 
                "arm_group_type": "Experimental", 
                "description": "NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess whether the daily use of NeutraSal will prevent or reduce dry mouth in patients\n      undergoing CPAP therapy for OSAS and improve CPAP compliance"
        }, 
        "brief_title": "NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy", 
        "condition": "Xerostomia", 
        "condition_browse": {
            "mesh_term": [
                "Sleep Apnea Syndromes", 
                "Xerostomia", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects diagnosed with Obstructive Sleep Apnea Syndrome (OSAS) who have started CPAP\n      treatment and have complained of dry mouth or developed worsening of a pre-existing dry\n      mouth as an effect of CPAP treatment will test the effectiveness of NeutraSal mouthwash in\n      preventing or reducing his/her dry mouth perceptions and improving their compliance with\n      CPAP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient should be above 18 years of age.\n\n          -  Patients who have been initiated on CPAP therapy after an initial diagnosis of OSAS\n             and have developed dry mouth or have worsening of pre-existing dry mouth condition,\n             as an effect of CPAP therapy.\n\n          -  Ability to attend visits at the research site\n\n          -  Patient should be able to read and/or understand and sign the consent form be willing\n             to participate in the research study\n\n        Exclusion Criteria:\n\n          -  Patients with open mouth sores at study entry.\n\n          -  Any pathology that, based on the judgement of the researcher, could negatively affect\n             the oral mucosa and subsequent treatment for xerostomia (immune disorders, etc.)\n\n          -  Patients using any other prophylactic mouthwashes.\n\n          -  Patients who are pregnant and/or nursing.\n\n          -  Patients becoming pregnant during the treatment period will be removed from data.\n\n          -  Patients on a low sodium diet\n\n          -  Patients currently on medication or treatment for xerostomia\n\n          -  Patients < 18 years of age\n\n          -  Hypersensitivity to any of the following ingredients- sodium chloride, sodium\n             phosphate, calcium chloride and sodium bicarbonate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107300", 
            "org_study_id": "CPAP"
        }, 
        "intervention": [
            {
                "arm_group_label": "NeutraSal", 
                "description": "NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.", 
                "intervention_name": "NeutraSal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal", 
                "intervention_name": "Placebo (for NeutraSal)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Obstructive Sleep Apnea Syndrome", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "lalch@musc.edu", 
                "last_name": "Chitra Lal, MD", 
                "phone": "843-792-3176"
            }, 
            "contact_backup": {
                "phone": "843-792-7776"
            }, 
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }, 
            "investigator": [
                {
                    "last_name": "Chitra Lal, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "J. Terrill Huggins, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "NeutraSal in the Management of Xerostomia in Obstructive Sleep Apnea Syndrome (OSAS) Patients Utilizing Continuous Positive Airway Pressure (CPAP) Therapy", 
        "overall_contact": {
            "email": "jonesash@musc.edu", 
            "last_name": "Ashley Warden", 
            "phone": "843-792-4349"
        }, 
        "overall_official": {
            "affiliation": "Medical University of South Carolina", 
            "last_name": "Chitra Lal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To observe the impact of NeutraSal on OSAS patients compliance to CPAP therapy compared to placebo.", 
            "measure": "Impact of NeutraSal on OSAS patients", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107300"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of South Carolina", 
            "investigator_full_name": "Chitra Lal", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To assess whether the daily use of NeutraSal will prevent or reduce dry mouth perception in OSAS patients undergoing CPAP therapy.  Dry Mouth perception will be measured by the subject's compliance with  the use of CPAP,  an Xerostomia Questionnaire, resting saliva pH testing, and product utilization based on subject's diary", 
            "measure": "Prevention or reduction of dry mouth with NeutraSal", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "collaborator": {
                "agency": "Invado Pharmaceuticals LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}